- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Serum Institute to develop US biotech firm Codagenix nasal COVID vaccine
![Serum Institute to develop US biotech firm Codagenix nasal COVID vaccine Serum Institute to develop US biotech firm Codagenix nasal COVID vaccine](https://medicaldialogues.in/h-upload/2020/06/30/750x450_131039-coronavirus-vaccine.webp)
New Delhi: Codagenix Inc said on Tuesday Serum Institute of India has started manufacturing the U.S. biotech firm's potential Covid-19 vaccine and it expects to begin early-stage human trial of the vaccine by the end of 2020 in the UK.
Serum Institute, the world's largest vaccine maker by number of doses produced, will develop Codagenix's CDX-005, which is delivered intranasally rather than via an injection.
Serum Institute is working on several vaccine candidates for the novel coronavirus - including potentially mass-producing the one from AstraZeneca-Oxford University that has garnered global headlines - as well as developing its own.
More than 150 potential vaccines are being developed and tested globally, with 38 in human trials, and candidates from Moderna Inc, Pfizer Inc and AstraZeneca Plc are already in late-stage trials.
serum institute of indiaserum institute of india newscodagenixcovid-19coronaviruscdx-005coronavirus vaccine
Source : ReutersRuchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story